The FDA wrote to Ranbaxy saying that while there were no data
integrity issues related to the company's filings for these two
drugs, the agency's original decisions granting approval were "in
error," the company said on Thursday.
Ranbaxy added that it has lost its six-months exclusivity on
launching a generic version of Valcyte.
"Ranbaxy is disappointed with this development and is actively
evaluating all available options to preserve its rights," the
company said in a statement.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Sunil Nair)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
[to top of second column]